&lt;p&gt;Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches&lt;/p&gt;

Palaia, Innocenza; Tomao, Federica; Sassu, Carolina Maria; Musacchio, Lucia; Panici, Pierluigi Benedetti

doi:10.2147/ott.s205950

Cited by 61 publications

(54 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, FCGBP was predicted to be involved in chemokine signaling pathways, as well as the innate and adaptive immune systems. Moreover, considering that the infiltration of immune cells (especially macrophages) is important for the overall survival of patients with ovarian cancer [ 8 , 9 ], we examined the association between FCGBP expression and the immune cell infiltration level and found that M2 macrophage infiltration increased, while M1 macrophage infiltration decreased in tissues with high FCGBP expression. Our results suggest potential functional role of FCGBP in ovarian cancer, thereby highlighting a mechanistic basis whereby FCGBP influences M2 macrophage polarization in the tumor microenvironment.…”

Section: Introductionmentioning

confidence: 99%

A bioinformatic analysis: the overexpression and clinical significance of FCGBP in ovarian cancer

Wang

Guan

Shang

et al. 2021

Aging

View full text Add to dashboard Cite

Fc fragment of IgG-binding protein (FCGBP) is differentially expressed in various tumors. However, the correlation between FCGBP and immune cell infiltration in ovarian cancer remains unclear. FCGBP expression was analyzed using The Cancer Genome Atlas (TCGA) pan-cancer data, and the ovarian cancer expression profile was analyzed using the Gene Expression Omnibus database. The clinical prognostic value of FCGBP was evaluated using clinical survival data from TCGA. Enrichment analysis of FCGBP was performed using the R package clusterProfiler. Based on known immune cell infiltration scores for samples found in TCGA, we analyzed the association between immune cell infiltration level and FCGBP expression. FCGBP was highly expressed and associated with poorer overall survival (p = 0.00051) and disease-specific survival (p = 0.0012) in ovarian cancer and other tumors. Additionally, high FCGBP expression correlated significantly with immune-related gene sets, including those involved in chemokine signaling pathways and innate and adaptive immunity. Further analysis showed that M2 macrophage infiltration increased and M1 macrophage infiltration decreased in tissues with high FCGBP expression. Our study suggests that FCGBP contributes to M2 macrophage polarization by acting as an oncogene in ovarian cancer. FCGBP may represent a clinically helpful biomarker for predicting overall survival of ovarian cancer patients.

show abstract

Section: Introductionmentioning

confidence: 99%

A bioinformatic analysis: the overexpression and clinical significance of FCGBP in ovarian cancer

Wang

Guan

Shang

et al. 2021

Aging

View full text Add to dashboard Cite

show abstract

“…Particularly, single-agent Abs against CTLA-4, PD-1 or PD-L1 revealed modest results in epithelial ovarian cancer with median response rates (RR) less than 15% and a control of disease rate less than 50% [ 25 , 26 ]. On the contrary, combinations of immunotherapy with chemotherapy, anti-angiogenic agents or poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising results in terms of ORR and median PFS [ 27 ]. However, monotherapy with pembrolizumab in women with MSI-high tumors seems to be a reasonable therapeutic option irrespective of the tumor location as it has already been mentioned above [ 14 ].…”

Section: Resultsmentioning

confidence: 99%

Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years

Koulouris

Tsagkaris

Nikolaou

2021

Toxins

View full text Add to dashboard Cite

Intense research on immunotherapy has been conducted during recent years. As advances in the field have started changing the landscape of cancer therapy, it is necessary to assess the impact of immunotherapeutic modalities in the treatment of various cancers. Ten years ago, in 2011, ipilimumab was the first of the newest immunotherapeutic drugs against cancer to be approved by the FDA. Then several drugs followed and formed a therapeutic arsenal to fight cancer. Initial studies were performed on metastatic patients, but there are currently several studies in patients with potentially curable cancers. All these developments have created a new environment for oncology which we will present in this article. This review examines the current evidence related to the impact of immunotherapy on various cancers and discusses its potential clinical and research implications, including its effectiveness in comparison to other treatment modalities (chemotherapy, radiotherapy), its toxicity and prospective research opportunities. While constant updates and further research is critical to understand the impact of immunotherapy in cancer therapy, not only does it seem to be important to assess the current state of knowledge highlighting the success but also to determine the challenging aspects of cancer immunotherapy.

show abstract

“…The TMB of NSCLC is $10-fold that of ovarian cancer [22]. In fact, clinical studies of ICBs indicated NSCLC rather than ovarian cancer was the preferred target [23,24]. These findings suggest that preexisting immunity levels are higher in patients with NSCLC than in patients with ovarian cancer.…”

Section: Discussionmentioning

confidence: 99%

Integrity of circulating cell-free DNA as a prognostic biomarker for vaccine therapy in patients with nonsmall cell lung cancer

Waki

Yokomizo

Yoshiyama

et al. 2021

Immunopharmacology and Immunotoxicology

View full text Add to dashboard Cite

Background: Many clinical trials of immune checkpoint blockade-based combination therapies are under way. Vaccine therapy is a promising partner of combination therapies. We have developed a personalized peptide vaccination and conducted clinical trials of it in patients with various cancers. At the present time, we have only a limited number of biomarkers related to the prognosis of vaccinetreated patients. Thus, new biomarkers are urgently needed. Methods: In this study, we investigated the plasma cell-free DNA (cfDNA) integrity-a ratio of the necrotic tumor cell-derived long cfDNA fragments to the total dead cell-derived short cfDNA fragments from genomic Alu elements-in patients with advanced nonsmall cell lung cancer during treatment with the personalized peptide vaccination. Results: We found that (1) the cfDNA integrity was decreased after the first cycle of vaccination, and (2) the patients with high prevaccination cfDNA integrity survived longer than those with low prevaccination integrity (median survival time (MST): 17.9 versus 9.0 months, respectively; hazard ratio (HR): 0.58, p ¼ .0049). A similar tendency was observed in postvaccination cfDNA integrity (MST: 16.4 vs 9.4 months; HR: 0.65, p ¼ .024). Conclusions: These results suggest that cfDNA integrity is a possible prognostic biomarker in patients treated with the personalized peptide vaccine.

show abstract

<p>Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches</p>

Cited by 61 publications

References 95 publications

A bioinformatic analysis: the overexpression and clinical significance of FCGBP in ovarian cancer

A bioinformatic analysis: the overexpression and clinical significance of FCGBP in ovarian cancer

Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years

Integrity of circulating cell-free DNA as a prognostic biomarker for vaccine therapy in patients with nonsmall cell lung cancer

Contact Info

Product

Resources

About